MedPath

Caffeine

Generic Name
Caffeine
Brand Names
Anacin, Arthriten Inflammatory Pain, Ascomp, Bc Arthritis, Bc Original Formula, Cafcit, Diurex, Dvorah, Esgic, Exaprin, Excedrin, Excedrin Tension Headache, Fioricet, Fioricet With Codeine, Fiorinal, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Midol Complete, Midol Cramps & Bodyaches, Migergot, Norgesic, Norgesic Forte, Orbivan, Orphengesic, Pamprin Max Formula, Peyona, Stanback Headache Powder Reformulated Jan 2011, Trezix, Trianal, Trianal C, Triatec, Triatec-8, Vanatol, Vanatol S, Vanquish, Vivarin, Peyona (previously Nymusa), Gencebok
Drug Type
Small Molecule
Chemical Formula
C8H10N4O2
CAS Number
58-08-2
Unique Ingredient Identifier
3G6A5W338E
Background

Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophylline and Theobromine. It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection.

The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999. According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely. Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants.

Indication

Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth. In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs. Caffeine has a broad range of over the counter uses, and is found in energy supplements, athletic enhancement products, pain relief products, as well as cosmetic products.

Associated Conditions
Acute Pain, Chronic Lung Disease of Prematurity, Common Cold, Dyspepsia, Fatigue, Fever, Flu caused by Influenza, Headache, Menstrual Pain, Myalgia, Pain, Pain caused by Rheumatism, Primary apnea of premature newborns, Respiratory Depression, Somnolence, Tension Headache, Toothache, Under-eyes Dark Circles, Vascular Headaches, Moderate Pain
Associated Therapies
Analgesia, Antacid therapy, Athletic Performance

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

Phase 4
Completed
Conditions
Transplant Rejection
Interventions
First Posted Date
2013-01-11
Last Posted Date
2014-06-27
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
45
Registration Number
NCT01766050
Locations
🇺🇸

Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States

Caffeine to Reduce Mechanical Ventilation in Preterm Infants

Not Applicable
Terminated
Conditions
Respiratory Failure
Prematurity
Apnea
Interventions
Other: Normal saline
First Posted Date
2012-12-18
Last Posted Date
2017-06-19
Lead Sponsor
University of Miami
Target Recruit Count
87
Registration Number
NCT01751724
Locations
🇺🇸

NICU, Holtz Children's Hospital, Jackson Health System, Miami, Florida, United States

Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T

Early Phase 1
Conditions
Psychotropic Drugs Effects
Interventions
First Posted Date
2012-12-11
Last Posted Date
2012-12-11
Lead Sponsor
Mclean Hospital
Target Recruit Count
12
Registration Number
NCT01747590
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

Caffeine as a Therapy for Parkinson's Disease

Phase 3
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Placebo
First Posted Date
2012-11-30
Last Posted Date
2017-03-22
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Target Recruit Count
119
Registration Number
NCT01738178
Locations
🇧🇷

Parana Parkinson Association - Pontifical Catholic University of Parana, Curitiba, PR, Brazil

🇨🇦

Movement Disorder Clinic - Deer Lodge Centre, Winnipeg, Manitoba, Canada

🇨🇦

The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada

and more 5 locations

The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man

Not Applicable
Completed
Conditions
Obesity
Interventions
Drug: caffeine, ephedrine, and leptin A
First Posted Date
2012-10-19
Last Posted Date
2015-12-18
Lead Sponsor
Pennington Biomedical Research Center
Target Recruit Count
45
Registration Number
NCT01710722
Locations
🇺🇸

Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

The Effects of Caffeine on Vestibular Evoked Myogenic Potentials in Healthy Subjects

Phase 4
Conditions
Healthy Subjects
Interventions
First Posted Date
2012-09-26
Last Posted Date
2012-10-02
Lead Sponsor
Hospital do Servidor Publico Estadual
Target Recruit Count
25
Registration Number
NCT01693809
Locations
🇧🇷

Hospital do Servidor Publico Estadual, São Paulo, Brazil

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
First Posted Date
2012-05-11
Last Posted Date
2020-12-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
39
Registration Number
NCT01596647
Locations
🇺🇸

Comprehensive Cancer Centers, Las Vegas, Nevada, United States

🇺🇸

University of Kansas Cancer Center Medical Center, Kansas City, Kansas, United States

🇺🇸

Henry Ford Hospital Henry Ford, Detroit, Michigan, United States

and more 2 locations

Development of Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2012-04-04
Last Posted Date
2012-04-04
Lead Sponsor
Inje University
Target Recruit Count
26
Registration Number
NCT01570569

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Phase 1
Completed
Conditions
Hepatitis C, Chronic
Interventions
First Posted Date
2012-02-03
Last Posted Date
2016-06-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
72
Registration Number
NCT01525628
Locations
🇺🇸

1241.27.0006 Boehringer Ingelheim Investigational Site, La Mesa, California, United States

🇺🇸

1241.27.0003 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States

🇺🇸

1241.27.0004 Boehringer Ingelheim Investigational Site, Marlton, New Jersey, United States

and more 13 locations
© Copyright 2025. All Rights Reserved by MedPath